Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.43 +0.9%	$3.50	$3.96 ▼ $12.00	$6.15M	1.55	7,305 shs	1,175 shs
AZRX AzurRx BioPharma	$0.41 +3.7%	$4.04	$3.36 ▼ $26.30	$3.78M	1.51	628,703 shs	111,759 shs
SXTC China SXT Pharmaceuticals	$1.83 +2.5%	$1.79	$0.95 ▼ $11.92	$28.89M	1.18	1.19 million shs	47,822 shs
UMRX Cogent Biosciences	$7.41 +2.6%	$10.50	$0.29 ▼ $3.72	$314.70M	3.93	1.22 million shs	1.78 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	+0.88%	+3.16%	+1.78%	+16.51%	-22.22%
AZRX AzurRx BioPharma	-2.38%	-18.19%	-9.92%	-5.01%	-60.16%
SXTC China SXT Pharmaceuticals	-7.29%	+3.49%	+34.85%	-27.05%	-79.40%
UMRX Cogent Biosciences	+0.56%	-0.28%	+32.72%	+26.22%	-12.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.3535 of 5 stars	0.0	3.0	0.0	0.0	1.6	0.0	0.6
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.59	N/A	N/A	$14.99 per share	0.23
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	14.97	N/A	N/A	$243.66 per share	0.01
UMRX Cogent Biosciences	$22.50M	13.99	N/A	N/A	$1.04 per share	7.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	8/11/2025 (Estimated)
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
AZRX AzurRx BioPharma	N/A	1.33	1.33
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
UMRX Cogent Biosciences	0.18	2.90	2.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
AZRX AzurRx BioPharma	6.27%
SXTC China SXT Pharmaceuticals	5.02%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
AZRX AzurRx BioPharma	7.30%
SXTC China SXT Pharmaceuticals	3.95%
UMRX Cogent Biosciences	31.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

SXTC, UMRX, AZRX, and AEZS Headlines

Recent News About These Companies

Cogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib Launch

June 11, 2025 | quiverquant.comQ

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now

May 13, 2025 | insidermonkey.com

Cogent Biosciences Advances with Promising Clinical Trials

May 6, 2025 | tipranks.com

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

May 5, 2025 | insidermonkey.com

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts

April 20, 2025 | insidermonkey.com

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 17, 2025 | msn.com

Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires

March 18, 2025 | msn.com

Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires?

March 17, 2025 | insidermonkey.com

Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank

March 10, 2025 | markets.businessinsider.com

Cogent Biosciences initiated with an Outperform at Scotiabank

March 7, 2025 | markets.businessinsider.com

Cogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last year

February 25, 2025 | markets.businessinsider.com

Cogent Biosciences sees cash runway into late 2026

February 25, 2025 | markets.businessinsider.com

Cogent Biosciences Inc (COGT) Stock: More Resilient Than It Appears

January 24, 2025 | bovnews.comB

Cogent Biosciences exec buys $332K in common stock

January 16, 2025 | markets.businessinsider.com

Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)

January 14, 2025 | markets.businessinsider.com

Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright

January 14, 2025 | markets.businessinsider.com

Cogent Biosciences (COGT) Gets a Buy from J.P. Morgan

December 19, 2024 | markets.businessinsider.com

Cogent Biosciences Reports Promising APEX Phase 2 Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis at ASH 2024

December 8, 2024 | quiverquant.comQ

Cogent Biosciences price target raised to $21 from $19 at JPMorgan

November 15, 2024 | markets.businessinsider.com

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

November 12, 2024 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, UMRX, AZRX, and AEZS Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$3.43 +0.03 (+0.88%)

As of 07/1/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.82 +0.05 (+2.53%)

As of 01:19 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time